All In Biotech

Drug Trial Radar · NCT05623267

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy

Last checked: Nov 20, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 346 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

346

Planned (sponsor's estimate)

Start

Jul 1, 2023

Primary completion

Dec 31, 2025

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.

Conditions

  • Limited Stage Small Cell Lung Cancer

Interventions

  • SugemalimabDrug

    Recombinant anti-PD-L1 fully human monoclonal antibody

  • PlaceboDrug

    Placebo of Sugemalimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progress Free Survival(PFS)Time frame: up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.